SelectScience
Join Free
Product NewsClinical Diagnostics

Expanding access to Alzheimer’s biomarker testing

Fujirebio
13 Aug 2026

Early diagnosis can make a meaningful difference for patients and families affected by Alzheimer’s disease and other neurological conditions. In this Fujirebio video, discover how decades of diagnostic innovation, investment in neurodiagnostics, and the work of the Fujirebio Neuro Center of Excellence are helping advance reliable biomarker testing.

Plus, explore Fujirebio’s open partnership model, which is designed to share innovations across platforms and broaden access to advanced assays for laboratories, physicians, and patients worldwide.

About the company

Fujirebio logo

Fujirebio

Fujirebio is global R&D-driven company constantly developing new in vitro diagnostics testing technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Our global teams located in Japan, Asia, Europe, and the US focus on delivering products with the highest quality standards to our customers and partners. We value CDMO partnerships with many of the world’s leading diagnostic companies, sharing knowledge, capabilities, and critical materials to supply, develop, or manufacture diagnostic solutions on a wide variety of platforms.

Company ProfileCompany Website

What does this video cover?

Fujirebio automated immunoassay analyzer in use

Fujirebio automated immunoassay analyzer in use

Topics covered in this video

  • Why early diagnosis matters for patients and families affected by Alzheimer’s disease
  • How Fujirebio is advancing biomarker innovation in neurodiagnostics
  • The role of the Fujirebio Neuro Center of Excellence in assay development and validation
  • Why real-world testing is important for proving assay reliability, consistency, and effectiveness
  • How Fujirebio’s open partnership model helps expand access to advanced biomarker testing across platforms

Related products

Request Quote for All Products

Lumipulse® G NfL Blood (CE marked (IVDR))

Fujirebio

Lumipulse G NfL Blood is a quantitative test for in vitro diagnostic use with the automated LUMIPULSE G System for the measurement of neurofilament light chain (NfL) in human blood (serum/plasma) in patients with neurological diseases.

(0)

Other videos from Fujirebio

Links

FujirebioCompany website

Related content

Tags

Clinical ChemistryBiochemistry (or clinical chemistry) involves the analysis of bodily fluids using chemical tests. Techniques used include HPLC, chromatography, spectroscopy, mass spectrometry, immunochemical, electrophoresis, turbidometric / spectrophotometric assay, MRI and ISE analysis. Tests are often carried out on plasma or serum but urine (urinalysis) and fecal specimens are also processed.ELISAEnzyme-linked immunosorbent assays (ELISA), also known as enzyme immunoassays (EIA), are used for the detection and quantification of proteins, peptides and antibodies in a sample. ELISA often comes in kit format, with pre-selected antibody pairs to detect specific proteins or biomarkers of diseases such as diabetes and obesity, or cardiovascular and neurological disorders. Detection is made possible with chemiluminescent, fluorescent or colorimetric substrates and detection instruments such as microplate / ELISA readers. Other kits available include: Enzyme-linked immunospot (ELISPOT) assays for the quantification of protein-producing cells and chemiluminescent immunoassays (CLIA) kits. Find the best ELISA kits and products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.BiomarkersBiomarkers are biological markers which can be measured and evaluated to indicate a biological state. The use of biomarkers in research and diagnosis can indicate a normal or disease state or drug response of cells / tissues. Biomarkers include genetic markers, cell surface markers such as antigens, antibodies or receptors and secreted molecules such as cytokines. An assay system is required for identification of biomarkers. :ImmunoassayImmunoassays are laboratory tests that utilize antibody-antigen interactions to detect specific substances. They are widely used in diagnostics for detecting diseases, drug testing, and environmental monitoring. These assays offer rapid, sensitive, and precise detection of biomarkers, making them invaluable in clinical and research labs. Browse our peer-reviewed product directory to compare immunoassay systems, read user reviews, and get pricing directly from manufacturers.Biomarker DiscoveryNeurodegenerationNeurodegeneration refers to the progressive deterioration of the structure and function of the nervous system, often seen in diseases like Alzheimer's and Parkinson's. Research focuses on early detection and potential therapies. Explore neurodegeneration research tools in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.Alzheimer's researchAlzheimer's disease is a neurodegenerative condition characterized by progressive memory loss and cognitive decline. Research focuses on understanding the molecular and cellular mechanisms of the disease, as well as developing effective treatments and diagnostic tools. Browse our peer-reviewed product directory to find the best Alzheimer's research products, compare options, check reviews, and get pricing directly from manufacturers.

Frequently asked questions

Show frequently asked questions

How does Fujirebio’s neurodiagnostic innovation support early diagnosis of Alzheimer’s disease?

Early diagnosis is highlighted as crucial for patients and families affected by Alzheimer’s disease. Fujirebio has invested decades in neurodiagnostics and was the first company in the early 1990s to develop a biomarker test for Alzheimer’s disease. Through the Fujirebio Neuro Center of Excellence, they validate assays for reliability, consistency, and effectiveness, helping advance dependable biomarker testing that supports earlier and more meaningful diagnosis.

What is the Fujirebio Neuro Center of Excellence and its role in biomarker testing?

The Fujirebio Neuro Center of Excellence is described as a global hub that brings together leading experts in the field. It drives research and development of neurodiagnostic assays, including biomarkers for Alzheimer’s disease. Beyond laboratory work, the center focuses on extensive real‑world testing and validation to prove reliability, consistency, and effectiveness, ensuring advanced biomarker tests can make a meaningful difference for patients and families.

How does Fujirebio’s open partnership model expand access to advanced neurodiagnostic assays?

Fujirebio uses an open business and partnership model designed to share innovations across platforms. By doing so, they broaden access to advanced assays and important tests for laboratories, physicians, and patients worldwide. This collaborative approach turns Fujirebio into an ‘innovation engine’, enabling broader access to reliable biomarker testing, reaching more patients, and supporting continued investment in solutions for complex neurological diseases.

Related videos